Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens

This publication has 9 references indexed in Scilit:

• The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
  Clinical Pharmacology & Therapeutics, 2003
• Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
  The Pharmacogenomics Journal, 2003
• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
  The Lancet, 2002
• Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.
  Published by Rockefeller University Press ,2001
• Identification and functional characterization of eight CYP3A4 protein variants.
  Published by Rockefeller University Press ,2001
• Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
  AIDS, 2001
• High-Performance Liquid Chromatography Method for Analyzing the Antiretroviral Agent Efavirenz in Human Plasma
  Therapeutic Drug Monitoring, 1999
• Efavirenz
  Drugs, 1998